Trial Profile

Phase II safety and efficacy trial of ATR-002 for treatment of influenza

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 20 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zapnometinib (Primary)
Indications Influenza virus infections
Focus Adverse reactions; Proof of concept; Therapeutic Use
Acronyms PanTher
Sponsors Atriva Therapeutics

Most Recent Events

18 Oct 2022 According to an Atriva Therapeutics media release, the study is planned to start in 2023 and will include patients with severe viral disease caused by influenzavirus, SARS-CoV-2 or respiratory syncytial virus (RSV).
21 Apr 2021 According to an Atriva Therapeutics media release, the company has planned to start this study later in 2021
29 May 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com